A Phase 2a, Multi-Centre, Randomised, Double-Blind, Parallel Group, Placebo-Controlled Study to Evaluate Efficacy, Safety and Tolerability of Inhaled GRC 17536, Administered for 4 Weeks, in Patients with Refractory Chronic Cough
Phase of Trial: Phase II
Latest Information Update: 31 Jan 2019
Price : $35 *
At a glance
- Drugs GRC 17536 (Primary)
- Indications Cough
- Focus Therapeutic Use
- Sponsors Glenmark Pharmaceuticals S.A.
- 26 Mar 2017 Status changed from active, no longer recruiting to completed.
- 26 Jul 2014 Status changed from recruiting to active, no longer recruiting as reported by United Kingdom Clinical Research Network record.
- 15 Oct 2013 New trial record